<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037840</url>
  </required_header>
  <id_info>
    <org_study_id>SXXin-AM-RF-EMF-in vivo</org_study_id>
    <nct_id>NCT03037840</nct_id>
  </id_info>
  <brief_title>Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients</brief_title>
  <official_title>Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients In Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong 999 Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 157th Hospital of PLA,China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown that tumor specific amplitude-modulated frequencies of radiofrequency
      electromagnetic fields that is associated with biofeedback upon exposure to in cancer
      patients. However, such discovery in other cancer patients are rare. And whether tumor
      specific frequencies can be found in Asian cancer patients remains unclear. The purpose of
      this study is to detect the tumor specific frequencies of Asian cancer patients in vivo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The measurements were safety guaranteed and were conducted in hospital. Before detecting, the
      patient will be already diagnosed with cancer. The doctor and the operator are responsible
      for the detecting. When cancer patients are exposure to the RF electromagnetic fields, the
      radial pulse amplitude, blood pressure, skin electrical resistance and breath will be
      monitored. Biofeedback parameters will be recorded at different modulation frequencies and
      analyzed in order to find the variation and tumor specific frequencies.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biofeedback response of cancer patients at the exposure of Low intensity amplitude-modulated radiofrequency electromagnetic fields</measure>
    <time_frame>within 20 min of exposure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Representation of autonomous response during the exposure of tumor specific frequencies modutated RF eletromagnetic fields</measure>
    <time_frame>within 20 min of exposure</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>cancer patients</arm_group_label>
    <description>Low intensity amplitude-modulated RF EMFs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy participators</arm_group_label>
    <description>Low intensity amplitude-modulated RF EMFs</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low intensity amplitude-modulated RF EMFs</intervention_name>
    <description>Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW</description>
    <arm_group_label>cancer patients</arm_group_label>
    <arm_group_label>healthy participators</arm_group_label>
    <other_name>Low intensity AM RF EMFs</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. The patients who are diagnosed with cancer disease

          2. Healthy participators
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of cancer Disease

        Exclusion Criteria:

          -  other patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Sherman Xuegang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Biomedical Engineering,Southern Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cai Linbo, master</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong 999 Brain Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhu Xiaoxia, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liu Xiantang, bachelor</last_name>
    <role>Study Director</role>
    <affiliation>The 157th Hospital of PLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Sherman Xuegang, professor</last_name>
    <phone>008613602733465</phone>
    <email>xxg@smu.edu.cn</email>
  </overall_contact>
  <reference>
    <citation>Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res. 2009 Apr 14;28:51. doi: 10.1186/1756-9966-28-51.</citation>
    <PMID>19366446</PMID>
  </reference>
  <reference>
    <citation>Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer. 2011 Aug 23;105(5):640-8. doi: 10.1038/bjc.2011.292. Epub 2011 Aug 9.</citation>
    <PMID>21829195</PMID>
  </reference>
  <reference>
    <citation>Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B. Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer. 2012 Jan 17;106(2):307-13. doi: 10.1038/bjc.2011.523. Epub 2011 Dec 1.</citation>
    <PMID>22134506</PMID>
  </reference>
  <reference>
    <citation>Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer. 2013 Nov;32(11):573-81. doi: 10.5732/cjc.013.10177. Review.</citation>
    <PMID>24206915</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern Medical University, China</investigator_affiliation>
    <investigator_full_name>Sherman Xuegang Xin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>RF EMF</keyword>
  <keyword>In Vivo</keyword>
  <keyword>tumor specific frequencies</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

